GW Pharmaceuticals PLC- (NASDAQ:GWPH) shares traded up 2.4% on Wednesday . The company traded as high as $88.23 and last traded at $87.04, with a volume of 299,065 shares trading hands. The stock had previously closed at $85.04.

A number of research analysts have recently weighed in on the company. Vetr raised GW Pharmaceuticals PLC- from a “buy” rating to a “strong-buy” rating and set a $91.16 price objective on the stock in a research report on Wednesday, August 17th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $147.00 price objective on shares of GW Pharmaceuticals PLC- in a research report on Saturday, August 13th. Cowen and Company reaffirmed a “buy” rating and set a $135.00 price objective on shares of GW Pharmaceuticals PLC- in a research report on Tuesday, August 9th. Cantor Fitzgerald lowered their price objective on GW Pharmaceuticals PLC- from $181.00 to $165.00 and set a “buy” rating on the stock in a research report on Tuesday, August 9th. Finally, Zacks Investment Research cut GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research report on Friday, July 29th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. GW Pharmaceuticals PLC- has a consensus rating of “Buy” and an average price target of $126.01.

The stock has a 50 day moving average of $90.56 and a 200 day moving average of $78.09. The stock’s market cap is $1.79 billion.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.21) by $1.15. The firm earned $3.10 million during the quarter, compared to analyst estimates of $3.63 million. During the same period in the prior year, the company posted ($0.09) earnings per share. The firm’s revenue for the quarter was down 73.3% on a year-over-year basis. Equities analysts predict that GW Pharmaceuticals PLC- will post ($4.52) earnings per share for the current fiscal year.

GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.